HOME >> MEDICINE >> NEWS
Only Eight Percent Of San Francisco HIV-Positive Urban Poor Receive Protease,,Inhibitors

Geneva, Switzerland -- In the first large-scale study of HIV treatment among the urban poor, University of California San Francisco AIDS researchers have found that very few of the HIV-infected poor receive drugs to combat the virus. Of those who do take anti-retroviral drugs, the researchers found a range of how well the patients adhered to their drug-taking regimens, ranging from 24 to 100 percent of prescribed levels. If subjects missed more than 10 percent of their drugs, the HIV treatment became ineffective.

The research project, called the REACH study for "Research in Access to Care in the Homeless," was started in response to concerns that the urban poor may develop resistant strains of HIV as a result of not adhering to their therapy. The UCSF team looked at how many of these people who were HIV-infected received therapy, how well they adhered to their regimens, and how the virus responded. David Bangsberg, MD, MPH, assistant professor of medicine at the UCSF AIDS Program at San Francisco General Hospital, was medical director of the study. He presented the research findings here today (July 1) at the 12th World AIDS Conference.

"This is the first study of anti-retroviral use in a population that makes up a growing portion of the HIV epidemic," said Andrew Moss, PhD, professor of epidemiology and medicine at UCSF and principal investigator. "Poor people are increasingly the main high-risk group for HIV."

Bangsberg said, "Most people think studies can't be done with the homeless because they are hard to keep track of. We found that to be untrue. Of 153 people in the study, we know where 151 of them are now, after more than a year." The UCSF team identified participants for the research project in free food lines, homeless shelters and low-income hotels and tested them for HIV infection. For those HIV-positive people on protease inhibitors, the researchers looked at three measures of adherence: self-report, random pill counts, and a digital
'"/>

Contact: Mitzi Baker
mabaker@itsa.ucsf.edu
(415) 476-2557
University of California - San Francisco
1-Jul-1998


Page: 1 2 3

Related medicine news :

1. Eight New Hartford doctoral fellows in Geriatric Social Work selected
2. Eighty five percent of practice nurses are underestimating the prevalence of insulin resistance in type 2 diabetes patients
3. UCSF And Eight Other Medical Centers Chosen For National Cancer Institutes Pediatric Brain Tumor Consortium
4. Express Scripts 1999 drug trend report: Seniors hit hardest by record 17.4-Percent prescription drug spending increase
5. New Study Finds Blacks Face 38 Percent Higher Stroke Risk
6. Osteoporosis Drug Evista (Raloxifene) Cuts Newly Diagnosed, Invasive Breast Cancer Risk By More Than 60 Percent
7. Study Finds Incidence Of Stroke Over 40 Percent Higher Than Previously Stated Figures
8. Rats Receiving Ginkgo Biloba Learn Quicker, Live 20 Percent Longer Than Controls, UB Study Finds
9. Congress of Neuological Surgeons meets in San Francisco
10. American Academy of Neurology presents 56th Annual Meeting in San Francisco, April 24 - May 1, 2004
11. NIH funds new brain imaging center at San Francisco VA Medical Center

Post Your Comments:
(Date:3/29/2015)... The Claudia Cohen Research Foundation and ... that Dr. Beth Y. Karlan has been selected as ... Prize for Outstanding Gynecologic Researcher. The $50,000 prize is ... Annual Meeting on Women's Cancer in Chicago. , Dr. ... at the Samuel Oschin Comprehensive Cancer Institute and Director ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for multiple ... injuries, according to new research released today at the American ... , “Our findings indicate that a 10 inch increase in ... a history of injury, a 10 mile per hour increase ... a history of injury, and playing for more than one ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
(Date:3/27/2015)... 27, 2015 As of February, InControl ... devices for women. "Shipping thousands of ... part is the hundreds of letters, emails and ... have been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
Cached News: